Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia
This study is intended for Chronic Lymphocytic Leukemia patients who have already undergone a first or second treatment with drugs named bendamustine and rituximab. It will observe the results of this treatment and evaluate its efficacy and side effects.
Chronic Lymphocytic Leukemia
DRUG: Bendamustine + Rituximab
Number of patients alive without progression, Progression-free survival, At 12 months from treatment start
Number of patients untreated, Time-to-next treatment, At 12 months from treatment start|Number of patients attaining Complete Response (CR), At six months, that is, at the end of the induction therapy.|Number of patients attainint CR/partial response (PR), At six months, that is, at the end of the induction therapy.|Number of patients alive, At 12 months from treatment start|Number of patients with grade 3-4 adverse events, At 12 months from treatment start
This cohort study will recruit chronic lymphocytic leukemia (CLL) patients who were treated with first and second-line Bendamustine plus Rituximab (BR) from January 2008 to December 2014 from European centres adhering to the GIMEMA group and the ERIC group, and aims at observing the progression-free survival in CLL patients.